Myocardial infarction related to cardiac procedures

Article written and reviewed by Dr Luca Moretti

An increase in troponin after PCI or bypass surgery is common, but does not automatically equal procedural infarction. Instrumentation, microembolization, cardioplegia, manipulation, and surgical trauma may cause myocardial injury; the definition of procedure-related infarction requires acute myocardial injury and objective confirmation of an ischemic complication, not a higher fixed troponin threshold. The distinction prevents two errors: calling every minimal release detected by ultrasensitive assays an infarction and overlooking a real complication behind the expected postprocedural elevation. The baseline value, pattern, ECG, angiography, and imaging must be collected systematically.
The Fourth Universal Definition separates type 4a within 48 hours of PCI, type 4b due to stent thrombosis, type 4c due to restenosis, and type 5 within 48 hours of CABG. Types 4b and 4c may occur long after the procedure and use clinical infarction criteria analogous to type 1; types 4a and 5 have conventional thresholds above five and ten times the 99th percentile, respectively, together with new evidence of ischemia.

Definitions serve care, quality, and research, but are not interchangeable. Universal Definition, SCAI, and ARC criteria use different biomarkers and thresholds and produce different incidences; a clinical article must state which system was applied; at the bedside, occlusion of a large branch with instability requires immediate correction before measurements are completed, whereas an isolated asymptomatic increase requires interpretation and recurrence prevention, not an automatic label.

Etiology, risk factors, pathogenesis, and pathophysiology

During PCI, the most common cause of injury is distal microembolization of thrombus, lipids, calcium, and debris released by a balloon, atherectomy, or stent. Small emboli produce foci of necrosis visible on CMR even when final epicardial flow appears normal; side-branch occlusion, extensive dissection, acute thrombosis, plaque shift, contained perforation, slow-flow, and no-reflow may cause greater loss. Duration of ischemia, branch size, and collateral circulation explain why angiographically similar complications have different consequences.
Long lesions, bifurcations, the left main, chronic occlusions, severe calcification, degenerated vein grafts, and high thrombus burden increase risk. Complex techniques require more balloons, stents, contrast, and time and multiply opportunities for ischemia; diabetes, kidney disease, age, anemia, and reduced ventricular function reduce reserve and amplify consequences. Elevated baseline troponin in ACS also makes it difficult to separate progression of the index event from the procedural effect. Preprocedural stability or decline is therefore an important diagnostic prerequisite.

Stent thrombosis results from interaction among patient, lesion, procedure, and treatment factors. Underexpansion, malapposition, edge dissection, residual thrombus, poor flow, and bifurcation favor early events; neoatherosclerosis, fracture, uncovered struts, and altered healing favor late events. Interruption of or inadequate response to antiplatelet therapy, ACS, diabetes, and low ejection fraction increase risk. Thrombosis may suddenly occlude the vessel and present as STEMI or death. OCT and IVUS identify the mechanism after flow is restored.

Restenosis is progressive narrowing due to neointimal hyperplasia, recoil, underexpansion, or neoatherosclerosis. It usually causes chronic angina, but rupture of neoatherosclerosis or severe progression may cause infarction due to restenosis, classified as procedure-related within 30 days or as primary myocardial infarction after 30 days. Small stents, long lesions, diabetes, calcification, and suboptimal technique increase risk. Distinguishing it from thrombosis is important because restenosis requires lesion preparation and treatment of the mechanical cause. A new plaque outside the treated segment causes primary myocardial infarction, not procedure-related infarction.

During CABG, ischemia may result from early graft occlusion, an anastomotic problem, kinking, spasm, flow competition, embolization, native coronary artery occlusion, or inadequate myocardial protection. Clamping, cardioplegia, and reperfusion cause diffuse injury, while direct manipulation and cannulation add trauma. Air or particulate embolism and low output may generate focal or global areas. A vein graft is susceptible to early thrombosis; an arterial graft may spasm. The cause determines whether surgical revision, PCI, or support is needed.
Cellular injury releases troponin in a relationship that is not perfectly proportional to necrotic mass. Surgery produces much higher values than PCI even without a territorial infarction, which is why thresholds differ. The biomarker reflects prognosis continuously, whereas definitions convert the continuum into operational categories; a new Q wave, regional defect, or angiographic complication increases specificity for clinically relevant ischemia. CMR may distinguish new areas but is unavailable in an emergency. Pathophysiology includes both focal vessel-related necrosis and diffuse injury from the procedure and systemic state.

Atherectomy and lithotripsy address severe calcium but may increase microembolization, slow-flow, or perforation. Selection depends on calcium depth, arc, and thickness assessed with imaging; inadequate preparation causes underexpansion, whereas overly aggressive preparation increases trauma. Device diameter and length must respect the vessel. Optimal technique is a preventive measure against procedural infarction.
In vein grafts, friable material and atherothrombotic burden favor distal embolization. Embolic protection is considered when technically feasible, while PCI of the native vessel may provide a more durable result; intracoronary vasodilators and gentle technique limit no-reflow. A severely degenerated graft may require an alternative strategy. Procedural benefit must exceed a particularly high risk.

During CABG, myocardial protection depends on cardioplegia, temperature, cross-clamp time, and distribution in stenotic territories. Hypertrophy, recent infarction, and reduced function increase vulnerability; a technically patent anastomosis may have insufficient flow because of spasm or competition. Intraoperative flow measurement and transesophageal echocardiography help recognize problems before closure. Prevention is integrated throughout the procedure.
Risk increases with multivessel PCI and complex staged procedures, but incomplete revascularization may leave ischemia. The choice between a single session and multiple stages considers contrast, stability, function, and complexity; a prolonged procedure is not by itself an infarction, whereas a brief passage may occlude an important branch. Fluoroscopy time and radiation are indicators of complexity. Auditing interprets context, not just the number.

Classification, anatomy, and evolution

Acute post-PCI myocardial injury is defined by a rise and/or fall in cardiac troponin with at least one value above the sex-specific 99th percentile. It does not require evidence of ischemia and may be small; if the baseline is already rising, attributing an increase to the procedure is problematic; the new event must be supported by clear clinical or angiographic signs. Samples before and after PCI are essential when classification matters.
Procedure-related myocardial infarction applies to coronary complications occurring within 30 days of PCI or other cardiac procedures. There is no single diagnostic troponin threshold for procedure-related infarction; after a percutaneous intervention, a value above five times the limit at approximately 6 hours only increases the probability of a complication. An ischemic complication must also be documented: if it occurs during the procedure or in the context of an acute infarction, both coronary evidence of the complication and a new regional abnormality or loss of viable myocardium on imaging are required; for subsequent events within 30 days, one of the two findings specified by the Fifth UDMI may suffice. The threshold alone is insufficient.

Stent or scaffold thrombosis is classified as a cause of procedure-related infarction if it occurs within 30 days in the treated territory; after 30 days it is a cause of primary myocardial infarction. It is temporally classified as acute within 24 hours, subacute from more than 24 hours to 30 days, late from more than 30 days to one year, and very late after one year. A separate category with criteria “analogous to type 1” no longer applies to stent thrombosis: within 30 days the criteria for procedure-related infarction apply, and after 30 days those for primary myocardial infarction apply. ARC distinguishes definite, probable, and possible thrombosis for studies; the universal definition requires evidence linking the event to the stent. The event may be occlusive and have very high mortality.

Restenosis of the treated segment may cause procedure-related infarction within 30 days; after 30 days, if it causes infarction, it is classified as primary myocardial infarction. Restenosis of the treated segment causing infarction within 30 days follows the criteria for procedure-related infarction; after 30 days it falls under primary myocardial infarction. In-stent neoatherosclerosis may become complicated and blur the boundary with thrombosis; intravascular imaging clarifies underexpansion, hyperplasia, neoatherosclerosis, and fracture. Edge stenosis or stenosis in another vessel must be attributed correctly. Classification informs prevention of renewed failure.

After CABG, there is no longer a category with a fixed diagnostic threshold of ten times the 99th percentile: procedure-related infarction includes complications within 30 days and requires the clinical and imaging criteria of the Fifth UDMI. Immediately after CABG, or when surgery is performed in the context of an acute infarction, both angiographic evidence of a coronary or graft complication and a new regional abnormality or loss of viable myocardium on imaging are required; new Q waves or ECG abnormalities alone do not confirm the diagnosis. New pathological Q waves alone do not define procedure-related infarction: they must occur within acute myocardial injury and the coronary and/or imaging confirmation criteria specified by the Fifth UDMI. Nonspecific ST-T changes after surgery are insufficient. Diagnosis is difficult because of pacing, the pericardium, and pre-existing abnormalities.

Evolution ranges from a small focus without deficit to a large territorial infarction. Branch occlusion may leave a limited scar; loss of a graft to the left anterior descending territory may cause shock. Major procedural injury is associated with mortality, but its significance also depends on the complexity that necessitated the procedure. Rapidly corrected thrombosis may recover; no-reflow and delay increase loss. Restenosis may recur if the mechanical mechanism is not corrected. Ejection fraction must be reassessed after stunning.
The major injury category proposed by recent consensus documents attempts to identify prognostically relevant post-PCI elevations even without all type 4a criteria. It does not replace Fifth UDMI criteria in current practice and must be declared in studies; the discrepancy reflects the continuum between biomarker elevation and clinical necrosis. Comparing trials without harmonizing definitions produces apparent conclusions. The clinical report must use recognizable nomenclature.

The SCAI definition uses higher CK-MB or troponin thresholds for clinically relevant events after PCI or CABG. It generates fewer events than the Universal Definition and may show different prognostic associations; criteria must not be combined or retrospectively selected to favor a result. Registries and publications must specify the biomarker, limit, and additional signs. Urgent care remains guided by the complication, not the name of the definition.
Timing distinguishes a periprocedural event from late failure. Procedure-related infarction includes coronary complications occurring within 30 days; thrombosis, restenosis, or graft failure after 30 days, if causing infarction, is classified as primary myocardial infarction; acute thrombosis during PCI and stent thrombosis occurring later within 30 days both fall under procedure-related myocardial infarction if they meet the diagnostic criteria. The angiographic sequence clarifies this boundary area.

Procedure-related infarction without pain may be suspected from new ECG changes or clinical deterioration, but diagnosis requires the coronary and/or imaging confirmation criteria of the Fifth UDMI. Symptoms have low sensitivity during sedation and in neuropathy, which is why the criteria do not depend on pain; a small elevation without additional evidence remains injury and must not be forced into the category. Prognostic significance increases with territory and new dysfunction. Communication distinguishes injury from infarction.

Clinical manifestations

During PCI, the most direct signal is persistent chest pain associated with new ST-segment changes, hypotension, or loss of flow. Brief pain from balloon inflation is expected and does not indicate infarction; sedation and analgesia may mask symptoms; branch occlusion may cause only an ECG change or arrhythmias, whereas main-vessel dissection rapidly causes shock. The operator observes flow, branches, and blush in real time. Onset after leaving the laboratory requires an immediate ECG and review of the images.
Stent thrombosis often presents as sudden ACS, STEMI, arrhythmia, or death. The patient may report DAPT interruption, but adherence does not exclude a mechanical problem. Subacute thrombosis during the first days may occur shortly after discharge and requires clear instructions; very late thrombosis may occur years later and must not be dismissed because the stent is old. The vessel and collateral circulation determine severity. Every suspicion requires urgent coronary angiography.

Restenosis more often causes progressive angina, but may present as infarction; within 30 days of treatment the event may be classified as procedure-related infarction, and after 30 days as primary myocardial infarction. Neoatherosclerosis may make the course more acute than homogeneous hyperplasia; the patient may have reduced activity and failed to recognize recurrence; systemic stress may unmask the stenosis. The ECG may show NSTEMI or, rarely, STEMI. The differential diagnosis includes a new plaque in another segment and thrombosis.
After CABG, sternotomy pain, ventilation, and sedation make symptoms of little use. Signs of a possible ischemic complication after cardiac surgery include unexpected low output, increasing inotropic requirements, arrhythmias, new Q waves, a regional abnormality, persistent lactate elevation, or difficulty separating from bypass; diffuse ST-T changes and elevated troponin are common and nonspecific. New territorial ST-segment elevation or hemodynamic deterioration requires transesophageal echocardiography and urgent graft assessment. Time is decisive for salvaging a territory from an occluded anastomosis.

Examination seeks shock, congestion, mitral regurgitation, tamponade, and vascular complications. After PCI, retroperitoneal hemorrhage may mimic ischemic shock; tamponade from perforation causes hypotension and venous distension; a contrast reaction causes noncoronary instability; after CABG, bleeding, tamponade, vasoplegia, and right ventricular dysfunction must be distinguished from infarction. Ultrasound and hemodynamic data separate frequently overlapping phenotypes. Troponin does not resolve the cause of shock.
Many events are clinically silent and detected by biomarkers. Their importance increases with magnitude, new Q waves, imaging, and a documented complication; a modest isolated release must not be communicated as a large infarction without context; the patient must receive a precise explanation of what occurred, how much myocardium was lost, which correction was performed, and how prognosis changes. The label may have psychological, insurance, and therapeutic consequences. Accuracy does not mean minimization.

New mitral regurgitation after PCI may result from papillary ischemia, circumflex occlusion, or rupture in a recent infarction. Edema and a murmur require immediate echocardiography; ejection fraction may appear preserved because of ejection into the atrium; branch revascularization, support, and surgery depend on the mechanism. Not every instance of postprocedural dyspnea is due to contrast or volume overload. Mechanical diagnosis changes intervention timing.
Poststernotomy pain is expected and reduces specificity, but a sudden change with instability or a new ECG finding must not automatically be attributed to the wound. Analgesia permits more reliable assessment without masking hemodynamics; ventilation and sedation make indirect signs decisive. Lactate that does not fall after volume correction suggests insufficient output. Examination must be serial.

In discharged patients, instructions about symptoms of thrombosis and DAPT are essential. Sudden pain must not be managed by taking an extra dose at home and waiting; emergency services must be called; dental or surgical procedures require coordination before medication is stopped. Risk depends on timing, complexity, and the reason for DAPT. A stent card reduces uninformed decisions.
A new ventricular arrhythmia during the procedure may be the first sign of ischemia from occlusion or no-reflow. Defibrillation and stabilization occur while angiography is checked; electrolytes and QT prolongation are corrected; bradycardia during right coronary PCI may be vagal or ischemic. Response to atropine does not exclude a mechanical complication. Rhythm is interpreted together with flow.

Investigations and diagnosis

Troponin should be measured before and serially after the procedure when clinical features suggest a coronary complication; routine measurement in every patient is not universally recommended. A normal or elevated baseline requires comparison with serial preprocedural and postprocedural values; a new rise is interpreted with assay-specific criteria and in the clinical context, without applying a fixed relative threshold of 20% or a defining absolute multiple. CK-MB is used in some research definitions and has useful kinetics, but the Fourth Definition gives priority to troponin. The method and limit must be stated. Systematic sampling produces more diagnoses than symptom-guided sampling.

Main criteria for myocardial infarctions related to revascularization

• Procedure-related infarction within 30 days of PCI: acute myocardial injury with compatible clinical or ECG features and confirmation through a coronary complication and/or a new regional abnormality or loss of viable myocardium according to time of onset; there is no single diagnostic troponin threshold.
• Stent or scaffold thrombosis: a cause of procedure-related infarction if it occurs within 30 days in the treated territory; after 30 days, a cause of primary myocardial infarction.
• Restenosis of the treated segment: a cause of procedure-related infarction if it occurs within 30 days; after 30 days, if it causes infarction, an etiology of primary myocardial infarction.
• Procedure-related infarction after CABG: unified criteria apply within 30 days; troponin above 35 times the limit at approximately 24 hours increases diagnostic probability but is not a defining threshold.

Preprocedural and postprocedural ECG identifies new Q waves, territorial elevation, or depression. After CABG, repolarization changes, pacing, and pericarditis reduce specificity; Q waves carry greater weight. An unchanged ECG does not exclude a small infarction or an electrically silent territory; continuous monitoring detects arrhythmias and transient ischemia. Comparison must consider the evolving index infarction. Abnormalities must be new and consistent with the territory of the complication.
Angiography documents dissection, vessel or branch occlusion, thrombus, embolization, slow-flow, and no-reflow. After stent thrombosis, OCT or IVUS clarifies underexpansion, malapposition, fracture, edge dissection, and neoatherosclerosis; after restenosis, it distinguishes hyperplasia, calcium, and mechanical constraint; after CABG, urgent angiography identifies an occluded graft or native-vessel problem when the patient is sufficiently stable; in shock, the choice among a hybrid suite, surgery, and PCI is multidisciplinary. An apparently good final image does not exclude distal microinfarctions.

Echocardiography seeks a new regional abnormality, ventricular function, regurgitation, effusion, and right ventricular dysfunction. Transesophageal echocardiography is particularly useful during and after CABG; endocardial contrast improves definition. A pre-existing abnormality must be documented before the procedure to avoid incorrect attribution. CMR is the most sensitive method for new focal necrosis and may quantify its volume, but is performed after stabilization. CT may assess graft patency in selected patients but does not replace intervention during instability. Imaging integrates, rather than replaces, temporal evidence.

The differential diagnosis includes progression of the index infarction, primary myocardial infarction in another vessel, secondary myocardial infarction due to anemia or shock, myocarditis, Takotsubo syndrome, and trauma. After PCI for ACS with troponin already rising, an angiographic complication or a new distribution is more informative than an isolated delta. After CABG, vasoplegia, bleeding, tamponade, pulmonary embolism, and global stunning may mimic procedure-related myocardial infarction. The team integrates the surgeon, interventional cardiologist, imaging specialist, and intensive-care specialist. The final classification must state uncertainty if the baseline prevents robust attribution.
CMR with late enhancement detects small periprocedural necroses and shows their distribution: adjacent to the lesion after branch occlusion or multifocal and distal after embolization. It quantifies mass better than biomarkers, but is not necessary for every increase; edema and microvascular obstruction add information. Devices, instability, and kidney function may limit it. Its main role is to clarify selected cases and mechanistic studies.

After CABG, graft CT may demonstrate patency in stable patients because of graft caliber and course, but does not always resolve distal anastomoses and calcified coronary arteries. During instability, invasive angiography offers therapeutic potential; transesophageal echocardiography identifies dysfunction and complications without transport. The choice must consider urgency and the consequence of the result. An accurate but delayed test may be clinically useless.
Diagnosis of reinfarction during an already biomarker-positive ACS requires new ischemia and a further significant increase from stable or falling values. A procedure performed while troponin is rising cannot be blamed based on the subsequent peak alone; a new occlusion, ECG territory, or imaging permits attribution. Sample times must appear in the report. Independent review is useful in trials.

Biomarker measurement should use the same laboratory and the same assay before and after whenever possible. Changing assays makes the delta inappropriate; hemolysis and interference may produce abnormal values; peak timing varies with the procedure and reperfusion, so a single sample underestimates or cannot date the event. The local protocol establishes samples without multiplying them unnecessarily. The upper limit is reported with the value.

Treatment and prognosis

Prevention begins with PCI planning: assessment of complexity, imaging for dimensions and calcium, a bifurcation strategy, protection of important branches, and adequate antithrombotic therapy. Radial access reduces bleeding; calcium preparation facilitates expansion; embolic protection in vein grafts is considered when technically appropriate. During the procedure, maintaining a wire in the branch, recognizing dissection, and checking flow permit early correction. Troponin does not replace careful technique. PCI without an indication exposes patients to procedural risk without benefit.
If occlusion or no-reflow occurs, flow is restored with a balloon, stent, selected aspiration, intracoronary vasodilators, or treatment of the dissection according to the mechanism. IIb/IIIa inhibitors are reserved for thrombus or bailout; hemodynamic support is selected in shock; occlusion of a small branch is not always recoverable without greater injury to the main vessel, and the decision balances territory against risk. Perforation requires a balloon, covered stent, embolization, or surgery. Treatment of the complication precedes formal classification.

Stent thrombosis requires urgent PCI, restoration of flow, and imaging after stabilization. Thrombus may be aspirated selectively; underexpansion is corrected with high-pressure balloons or calcium modification; dissections and diseased edges may require another stent. P2Y12 therapy is reloaded or changed with consideration of adherence, interactions, and risk. Merely adding a stent without correcting the cause favors recurrence. Genetic or platelet testing is reserved for selected scenarios. Antithrombotic duration is recalibrated after the event.

Restenosis is treated according to the intravascular mechanism: expansion of the structure, calcium modification, a drug-coated balloon, or another drug-eluting stent. Brachytherapy or bypass surgery are options in selected recurrences. Infarction due to restenosis receives infarction treatment and prevention; classification is procedure-related if the event occurs within 30 days and primary if it occurs after 30 days. After CABG with suspected occlusion, angiography and the Heart Team decide among PCI of the graft, the native vessel, or surgical revision. Instability requires support, control of bleeding, and rapid revascularization. PCI of a fresh vein graft entails embolic risk and requires experience.

After stabilization, antiplatelet therapy, an intensive statin, heart-failure treatment, and rehabilitation follow anatomy, the stent, and function. Bleeding may require changes, but early DAPT interruptions must be agreed with interventional cardiology. Echocardiography and, if necessary, CMR quantify the loss. An isolated increase without infarction does not automatically require prolonged DAPT, but suggests review of technique and risk. Renal and hemoglobin monitoring completes follow-up. Secondary prevention concerns the entire atherosclerotic disease.

Prognosis depends more on clinically relevant necrosis and the complication than on minimally exceeding a threshold. New Q waves, vessel occlusion, extensive CMR enhancement, and dysfunction predict worse outcomes; small isolated increases are confounded by baseline complexity and have weaker associations. Infarction due to stent thrombosis has high acute risk and potential for recurrence; infarction due to restenosis indicates local failure; procedure-related infarction after surgery may cause shock and mortality. Different definitions in trials alter comparisons between PCI and CABG. Communication must report criteria and impact, not merely the code.
Antithrombotic therapy during PCI balances thrombosis against bleeding. Heparin is dosed and monitored according to the strategy; bivalirudin is an alternative in selected contexts; IIb/IIIa inhibitors are bailout for thrombus and no-reflow; insufficient anticoagulation favors catheter thrombosis, whereas excessive anticoagulation favors hemorrhage and tamponade. The postprocedural regimen depends on the stent and chronic indication. Reconciliation prevents overlap.

Intravascular imaging improves expansion and apposition in complex lesions. OCT measures area and edges at high resolution but requires contrast; IVUS is useful in the left main with less contrast, but calcium causes acoustic shadowing and prevents measurement of its thickness; the result must be translated into a concrete correction. An uninterpreted image does not prevent complications. Team expertise is part of effectiveness.
Follow-up after procedure-related myocardial infarction includes ventricular function, symptoms, adherence, and the technical cause. A complication must not be hidden from the patient, but should be explained without automatically equating it to a large spontaneous infarction; multidisciplinary auditing identifies preventable problems and improves protocols. Discussion distinguishes the inherent risk of complexity from technical error. Transparency and learning are compatible.

After a major event, treatment of postprocedural heart failure follows ejection fraction, congestion, and blood pressure. An ACE inhibitor or ARB, beta-blocker, and mineralocorticoid receptor antagonist are introduced when stable; reassessment separates stunning from permanent deficit; a new scar may alter indications for rehabilitation and devices. Follow-up is not limited to stent patency. Organ function guides doses.

Complications

Extensive procedural loss may cause cardiogenic shock, edema, ischemic mitral regurgitation, and arrhythmias. Occlusion of a dominant coronary artery or essential graft rapidly compromises output; lactate, ultrasound, and angiography guide revascularization and support; no-reflow may persist despite an open vessel and predict remodeling. Ventricular arrhythmias require defibrillation and correction of ischemia. A small infarction in a patient with an already low ejection fraction may have disproportionate consequences.
PCI complications include perforation and tamponade, dissection, branch occlusion, coronary or systemic embolism, stroke, and vascular-access complications. Perforation may require pericardiocentesis and a covered stent; a retroperitoneal hematoma may mimic cardiogenic shock; contrast, hypotension, and atheroembolism contribute to kidney injury. Allergy and volume overload are alternative diagnoses for postprocedural dyspnea. Differential recognition prevents every deterioration from being attributed to infarction.

After CABG, bleeding, tamponade, vasoplegia, stroke, kidney failure, atrial fibrillation, infection, and respiratory failure may overlap with procedure-related myocardial infarction. Low output may be ischemic or caused by stunning, hypovolemia, tamponade, or right ventricular dysfunction; urgent revascularization may increase bleeding, making coordination essential. Early graft occlusion may remain silent until dysfunction develops. Surveillance integrates drainage, hemodynamics, ECG, echocardiography, and biomarkers.
Recurrent thrombosis is favored by an uncorrected mechanical cause, nonadherence, selected drug resistance, and a prothrombotic state. Each recurrence causes further myocardial loss and increases mortality. Repeated restenosis may create multiple metal layers and make treatment progressively difficult; imaging and selection of a drug-coated balloon, brachytherapy, or bypass surgery avoid simple stent layering. The patient must understand the role of DAPT and communicate before noncardiac procedures. Future perioperative management is documented.

Major bleeding competes with thrombotic risk. DAPT, anticoagulation, surgery, and access sites may cause gastrointestinal, intracranial, or access-site hemorrhage; transfusions and drug discontinuation affect prognosis. A patient with atrial fibrillation requires a brief, rational combined regimen; thrombocytopenia may result from heparin, IIb/IIIa inhibitors, surgery, or consumption. Renal dosing and gastroprotection reduce risk. Every change after hemorrhage must consider time since stenting and stent complexity.
In the long term, remodeling and scar may cause heart failure, ventricular tachycardia, thrombus, and sudden death. Unrecognized procedural injury may explain failure to improve after revascularization; an excessive label may instead cause anxiety and unnecessary treatment; reassessment of ejection fraction, symptom control, and secondary prevention define recovery. Procedural quality, complication auditing, and registries with transparent definitions improve future care. Procedural infarction is therefore both a clinical event and a process indicator, without confusing inevitability with preventability.

Limb ischemia and access complications may occur after support devices or femoral access. Hematoma, pseudoaneurysm, fistula, and occlusion require pulse examination, hemoglobin measurement, and ultrasound; radial access reduces many bleeding events but may cause radial occlusion. Device removal must follow anticoagulation and perfusion status. Extracardiac injury contributes to prognosis.
Neurological injury may result from aortic embolism, atrial fibrillation, hypoperfusion, or hemorrhage. A deficit after PCI or CABG requires immediate imaging and coordination, taking antithrombotic drugs and recent surgery into account; delirium must not mask a focal stroke. Risk increases with age and an atheromatous aorta. Prevention and treatment depend on the mechanism.

Infection of the sternum or access site occurs later than infarction but may aggravate inflammation and demand. Fever after CABG is not always infection, but instability and cultures guide investigation; prosthetic infection or endocarditis may cause coronary embolism. Glycemic control, asepsis, and wound care reduce risk. Follow-up must include local signs.
Radiation exposure does not cause infarction, but very long procedures may produce skin injury and increase operator risk. Dose-area product and air kerma are monitored and communicated if follow-up thresholds are exceeded; reducing unnecessary fluoroscopy does not compromise quality. Complexity that increases radiation often coincides with ischemic risk. Procedural safety encompasses both.